ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

obexelimab

Also written as “Obexelimab” and “XmAb5871”.

Its studies are mostly in Lupus Erythematosus, Systemic · Immunoglobulin G4-Related Disease · Multiple Sclerosis · Anemia, Hemolytic, Autoimmune, led by 2 companies.

Drug pageObexelimab: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 14, 20227 company-led studies, 4 open or runningLicense: Xencor → Zenas BioPharma, Nov 2021

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zenas BioPharma (USA)its history only44 open or runningphase 3since Dec 14, 2022Dec 14, 2022none ahead
Xencor30 open or runningphase 2since Jan 8, 2016Jan 8, 2016none ahead
  • Named in bristol myers squibb’s own pipeline as obexelimab, phase 4, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Bristol-Myers Squibb, PPD DEVELOPMENT, LP, ICON and Parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Xencor only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2016First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT02725515 · 105 enrolled · United States
  2. Mar 4, 2016Phase 2 study in Immunoglobulin G4-Related DiseaseNCT02725476 · 20 enrolled · United States
  3. Aug 2, 2016Phase 1 study in Healthy VolunteersNCT02867098 · 50 enrolled · United States
  4. Jun 9, 2018Named obexelimabINNProposed as its International Nonproprietary Name in WHO's List 119
  5. Nov 21, 2021Zenas BioPharma licensed it from XencorLicenseWorldwide rights · announced · Zenas BioPharma and Xencor (release)

TargetBeta

“A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultan…”NCIt, read by Claude

Studies

All 3 Xencor leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02867098Healthy Volunteers · United States1CompletedOct 21, 201650
NCT02725476Immunoglobulin G4-Related Disease · United States2CompletedDec 201720
NCT02725515Lupus Erythematosus, Systemic · United States2CompletedJul 17, 2018105

How it is read

Names in the registry

  • “Obexelimab”, 5 entries
  • “XmAb5871”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.